跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ALBRIOZA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ALBRIOZA
Authorized
STANDARD
ALBRIOZA
Amylyx Pharmaceuticals
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
a3aa7a3f31b042ff
Company
Amylyx Pharmaceuticals
Type
Standard
Approval Details
Approval Id
a3aa7a3f31b042ff
Drug Approval Canada Name
ALBRIOZA
Product Name
ALBRIOZA
Status
Cancelled Post Market
Status Date
2024-09-23
Original Market Date
2022-07-29
Din
02527707
Drug Class
Human
Dosage Form
Powder For Suspension
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:92.00
Atc Original
N07XX19 SODIUM PHENYLBUTYRATE AND URSODOXICOLTAURINE
Atc Name
n 07 xx 19
Aig Number
0263762001
Company Name
Amylyx Pharmaceuticals
Company Address
43 Thorndike Street, Cambridge, Massachusetts, United States, 02141
Company Detail Path
/organization/amylyx-pharmaceuticals
Company Information
Pharmaceutical Company Name
Amylyx Pharmaceuticals
Country Name
United States
Province Name
Massachusetts
City Name
马萨诸塞州米德尔塞克斯县
Address
43 Thorndike St Ste 12
Website
http://www.amylyx.com
Active Ingredients
URSODOXICOLTAURINE
1 G / SACHET
SODIUM PHENYLBUTYRATE
3 G / SACHET
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
a3aa7a3f31b042ff
Type
Standard
Back to Health Canada Approvals